Nissim Darvish Net Worth

What's Nissim Darvish's mailing address?

Nissim's mailing address filed with the SEC is C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT RD, STE 120, RALEIGH, NC, 27615.

Insiders trading at 9 Meters Biopharma

Over the last 5 years, insiders at 9 Meters Biopharma have traded over $20,934,964 worth of 9 Meters Biopharma stock and bought 2,247,050 units worth $1,572,701 . The most active insiders traders include Israel Gp Ltd.Orbi Med Isra..., Mark A Sirgo, eJohn Temperato. On average, 9 Meters Biopharma executives and independent directors trade stock every 35 days with the average trade being worth of $45,283. The most recent stock trade was executed by Bethany Sensenig on 21 April 2023, trading 9,100 units of NMTR stock currently worth $11,011.

What does 9 Meters Biopharma do?

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.

9 Meters Biopharma executives and stock owners

9 Meters Biopharma executives and other stock owners filed with the SEC include:

• John Temperato,
  Pres, CEO & Director
• Dr. Patrick H. Griffin,
  Chief Medical Officer
• Edward J. Sitar CPA, CPA,
  Chief Financial Officer
• Sarah Liu M.B.A.,
  Chief Commercial Officer
• Albert J. Medwar M.B.A., MBA,
  Sr. VP of Investor Relations & Corp. Communications
• Bethany Sensenig C.M.A., M.B.A.,
  Chief Financial Officer
• Dr. Nir Barak M.D.,
  Sr. VP of Scientific Affairs
• Dr. Elena Verdu M.D., Ph.D.,
  Clinical & Scientific Advisor and Consultant
• Dr. Ciaran P. Kelly M.D.,
  Clinical & Scientific Advisor and Consultant
• Joseph A. Murray,
  Clinical & Scientific Advisor and Consultant
• Dr. Peter H. R. Green M.D.,
  Clinical & Scientific Advisor and Consultant
• Dr. Nir Barak,
  Sr. VP of Scientific Affairs
• Jerry Gardner,
  Head of Clinical Strategy
• Sireesh Appajosyula Pharm.D.,
  Sr. VP of Corp. Devel. & Operations
• Samantha Ventimiglia,
  Director
• Bethany Sensenig,
  Chief Financial Officer
• John Temperato,
  Chief Executive Officer
• Edward J Sitar,
  Chief Financial Officer
• Lorin K Johnson,
  Director
• Israel Gp Ltd.Orbi Med Isra...,
  
• Nissim Darvish,
  Director
• Sandeep Laumas,
  Director
• Mark A Sirgo,
  Director
• Saira Ramasastry,
  Director
• Roy Proujansky,
  Director
• Yehuda Michael Rice,
  Director
• Jay P. Madan,
  President
• Anthony E Iii Maida,
  Director
• Michael T. Constantino,
  Director